INGN News & Events

Reports Q1 revenue $85.1M, two estimates $82.4M. "Our first quarter revenue exceeded our outlook with revenue growth of 3.4% as we continue to execute on our clinical and strategic priorities that we believe will position us for growth acceleration and improved profitability in the second half of the year and beyond," said Kevin Smith, Inogen's Chief Executive Officer. "Our progress reflects the power of our strategy as we expand our addressable markets, differentiate our portfolio with clinical evidence, and broaden our portfolio through innovation as we generate long-term sustained growth, profitability and value creation for our stockholders."

Inogen backs FY26 revenue view $366M-$373M, two estimates $368.9M

Inogen announced the following leadership appointments designed to accelerate the company's next phase of growth. Jason Richardson has been appointed Chief Financial Officer, effective April 6, 2026.Richardson succeeds Michael Bourque, who will step down from his role as Chief Financial Officer on that date. Bourque will serve in an advisory capacity until June 30, 2026, to ensure a smooth transition. Dominic Hulton has been appointed Chief Marketing Officer, effective April 1, 2026. Mr. Hulton is a globally experienced commercial leader with over 20 years of experience driving growth, expanding markets, and leading organizational transformation in medical technology. Mr. Hulton spent the last 11 years at Insulet Corporation, where he served as Vice President of International Marketing and Sales Excellence. In that role, he led global product launches, built cross-functional teams and scaled commercial operations.